The interaction between two proteins may play a role in Cushing’s disease tumors, potentially signaling a new approach to treatment, a study found. The PPP1R17 protein may help pituitary tumors that cause Cushing’s grow by blocking the activity of another protein, PP2A. Gilenya (fingolimod), a treatment approved in…
News
An experimental device designed to continuously measure cortisol and help diagnose and manage cortisol-related disorders, including Cushing’s disease, received breakthrough device designation from the U.S. Food and Drug Administration (FDA). The designation is intended for medical devices that may provide more effective diagnosis or treatment for life-threatening or irreversibly…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Lundbeck’s asedebart, a designation that may provide incentives for the development of this experimental antibody for endogenous Cushing’s syndrome. A Phase 2 trial is currently underway in people with Cushing’s disease, one form of the…
A study tied high cortisol in Cushing’s disease to an increase in certain blood cells not explained by the presence of the disease-causing tumor, suggesting that simple blood tests may help doctors monitor patients and their response to treatment. “Routine complete blood counts may serve as accessible biomarkers for…
People with Cushing’s disease often do an unusual amount of eating at night — but this behavior is driven mainly by mental health challenges and sleep disturbances, not because of the hormonal imbalance that underlies the disease. That’s according to a study, “Night…
Asedebart, an experimental treatment designed to ease symptoms in Cushing’s disease and other forms of endogenous Cushing’s syndrome, has been granted orphan drug status in the European Union. That designation, awarded to the Lundbeck therapy by the European Commission, aims to incentivize the development of treatments for rare…
People with Cushing’s syndrome may continue to have excess abdominal fat and diabetes years after achieving disease remission, putting them at an increased risk of experiencing cardiovascular, or heart-related, problems, a new study from Europe found. The data showed that, seven years after remission, individuals who’d had Cushing’s were more…
An exceptionally small pituitary tumor caused severe Cushing’s disease in a young man, leading doctors to take an unusual treatment approach after determining the disease-causing microadenoma would be too difficult to remove surgically, according to a case report from Iraq. Instead of surgery — the standard treatment for…
People with Cushing’s syndrome may experience lasting fatigue, reduced work ability, and disability years after treatment, including during remission, a new study shows. Researchers found that people with both active Cushing’s and disease in remission reported poor work ability. Among those in remission, fatigue and disability were also common, showing…
Japanese children with Cushing’s disease often went years before receiving a diagnosis, but surgery led to remission in most of those with outcome data. Measures of growth and body mass index also improved during follow-up, a study suggests. Researchers noted that although the…
Recent Posts
- Getting vaccinated takes a toll on me as someone with Cushing’s disease
- Protein interaction could point to new Cushing’s treatment approach
- Chronic stress from Cushing’s causes long-term memory loss for me
- FDA gives breakthrough status to continuous cortisol monitoring device
- Embracing the power of hope in life with Cushing’s disease
- FDA grants orphan drug status to experimental Cushing’s therapy
- The buffalo hump is one of my least favorite parts of Cushing’s disease
- Simple blood tests may help doctors monitor Cushing’s disease
- Let’s talk about sex and chronic illness
- Mental health challenges, poor sleep drive night eating in Cushing’s